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Abstract 
Ghrelin is a peptide hormone possessing a variety of physiological and pharmacological actions. This study aims to 
investigate the anti-inflammatory effects of exogenous ghrelin on chemically induced colitis in genetically predis-
posed lean (TSNO) and obese (TSOD) mice after different schedule of administration. To induce colitis, animals 
were given drinking water containing 2% dextran sodium sulfate (DSS) for 5 days. The TSOD and TSNO mice 
received daily intraperitoneal injections with saline (100 μl/day) or ghrelin (70 nmol/kg/day) for 5 days simultane-
ously or after DSS treatment. The severity of colitis was assessed by measuring body weight, colon length, histo-
logical analysis, plasma tumor necrosis factor  (TNFconcentration and expression of pro-inflammatory cyto-
kines in the colonic mucosa. At day 10, ghrelin administered after the DSS treatment slightly enhanced colonic in-
flammation in TSNO mice. On the other hand, ghrelin administration resulted in the partial improvement of colonic 
inflammation in TSOD mice. Furthermore, ghrelin administered simultaneously with DSS treatment might have 
slightly ameliorated some inflammation, as indicated by values compared with the after-treatment mice. Our find-
ings suggested that the effects of ghrelin on chemically induced colitis were different between lean and obese mice, 
and depend on the timing of ghrelin treatment. Therefore, we should consider these points when using ghrelin as an 
anti-inflammatory agent in inflammation models. 
 
Introduction 
Inflammatory bowel disease (IBD) is a chronic dis-
ease that causes unexplained inflammation of the di-
gestive tract, mainly consisting of ulcerative colitis 
(UC) and Crohn's disease [21]. UC forms erosions and 
ulcers in the large intestine, and shows characteristic 
clinical symptoms such as diarrhea, bloody stools, ab-
dominal pain, and weight loss [21]. UC has been rap-
idly increasing in Japan since 1970, and is designated 
as an intractable disease since its etiology is still un-
clear and an effective treatment strategy has not been 
established. Although the pathogenesis is unknown, it 
has been suggested that persistent inflammation and an 
antigen causing hyperimmune response in the intesti-
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nal tract via immunocompetent cells, both contribute to 
the development of UC [1]. In addition, there is 
mounting evidence that both genetic and environmen-
tal factors are also intricately involved [20]. IBD pa-
tients also have a high risk of colon cancer [7], because 
chronic inflammation is one of the major causes of 
carcinogenesis.  
Ghrelin, a peptide hormone composed of 28 amino 
acids with O-n-octanoyl acid modification at the serine 
3 position, is mainly secreted by the endocrine cells of 
both the stomach and hypothalamus, and exhibits a 
variety of physiological functions, such as modulation 
of food intake and energy homeostasis [12]. Further-
more, there is accumulating evidence suggesting that 
ghrelin has significant anti-inflammatory activities in 
various tissues [24, 25]. Previous studies have reported 
that ghrelin shows protective and healing effects in the 
gastrointestinal tract. Pretreatment with ghrelin reduces 
gastric alendronate [9], as well as accelerates the heal-
ing of gastric ulcers induced by acetic acid [3]. Ghrelin 
reduces intestinal inflammation in mouse and rat mod-
els of IBD [6, 13, 19]. On the other hand, some inves-
tigators reported the pro-inflammatory effect of exog-
enous ghrelin [5, 22]. It has been suggested that the 
anti-inflammatory effect of ghrelin is demonstrated by 
different results depending on the specific experi-
mental conditions used such as its dose or timing of 
administration.  
Obesity causes major adverse health outcomes such 
as type 2 diabetes, cardiovascular diseases, and 
dyslipidemia. Both obesity and UC are known as 
chronic inflammatory diseases, since they also cause 
increases in immune cells and pro-inflammatory cyto-
kines. However, the relationship between obesity and 
the development of colitis has not been fully under-
stood. In obese mice, DSS-induced colitis worsened 
when compared with lean mice. In these cases, exper-
imental colitis and obesity were aggravating factors for 
each disease [26]. In contrast, in obese rats treated with 
trinitrobenzene sulfonic acid, both colitis and colonic 
damage decreased when compared with lean mice [8]. 
Therefore, the relationship between obesity and colitis 
remains unclear. In order to clarify the relationship of 
obesity and colitis, and the anti-inflammatory role of 
ghrelin on colitis, further studies focusing are really 
needed. 
There have been few reports about the efficacy of 
ghrelin on colitis developed in obese animals. Since 
ghrelin has a fat accumulation effect [28], it is inter-
esting to investigate the anti-inflammatory effects of 
ghrelin on colitis in obese individuals. We, therefore, 
in the current study, attempted to elucidate whether 
exogenous ghrelin exerts any anti-inflammatory effects 
on dextran sodium sulfate (DSS)-induced colitis in 
obese (TSOD) and lean (TSNO) mice, and if it made a 
difference depending on the time when ghrelin was 
administered.  
 
Materials and Methods 
Animals 
Healthy 8-week-old male TSNO mice (mean body 
weight ± SD: 29.7 ± 1.7 g) and TSOD mice (mean 
body weight ± SD: 42.5 ± 2.7 g) were obtained from 
Sankyo Lab Service Corporation, Inc. (Tokyo, Japan). 
They were housed in a specific pathogen-free facility 
at controlled temperature (25°C) with alternating 
12:12-h light-dark cycles. Standard mouse chow pel-
lets (CE-2, CLEA Japan, Inc., Tokyo) and tap water 
were supplied ad libitum. This study was approved by 
the Animal Ethics Committee of Rakuno University 
(VH25A9).  
 
Induction of colitis and administration of 
ghrelin 
Colitis was induced by adding 2% (wt/vol) DSS 
(molecular mass 36,000–50,000 Da, MP Biomedicals, 
Solon, OH, USA) to the drinking water for 5 days ad 
libitum. After one week of acclimatization, 
9-week-old male mice were randomly divided into 
four groups (n = 6 per group, Fig. 1). Group 1 (vehi-
cle control) was administered saline (100 μl) by in-
traperitoneal (i.p.) injection once per day from day 5 
to day 10. Group 2 (DSS alone) was treated with 2% 
(wt/vol) DSS in their drinking water from day 0 to 
day 5 to induce colitis and then were administered 
saline by the same method used for Group 1. Group 3 
(DSS + ghrelin) was administered 2% DSS and sim-
ultaneously treated with daily i.p. injections of 
ghrelin (Peptide institute, Inc., Osaka, Japan) at a 
dose of 70 nmol/kg body weight from day 0 to day 5. 
Group 4 (DSS → ghrelin) was given 2% DSS in their 
drinking water from day 0 to day 5, and then was 
given daily i.p. injections of ghrelin from day 5 to day 
10. Ghrelin and saline i.p. injections were conducted 
at 10:30 AM on each administration day. Mice were 
monitored daily for reduction in body weight, diar-
rhea, and bloody stools. After an overnight fasting 
(for about 12 h), all animals were anesthetized with 
pentobarbital (40mg/kg, i.p.) in the morning on day 
10 and blood was collected from the caudal vena cava. 
After sacrifice, tissues (colon, liver, and spleen) were 
removed for the experimental analysis.  
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Histopathological grading of colitis 
After measurement of the colon length, the large bow-
els were fixed in 10% (wt/vol) buffered formalin for 
histopathological examination. Inflammation in the 
large bowel was scored on the hematoxylin and eosin 
(H&E)-stained sections. Large intestinal inflammation 
was graded according to the morphological criteria 
described by Cooper et al. [4]: grade 0, normal ap-
pearance; grade 1, shortening and loss of the basal 1/3 
if the actual crypts with mild inflammation in the mu-
cosa; grade 2, loss of the basal 2/3 of the crypts with 
moderate inflammation in the mucosa; grade 3, loss of 
all of the crypts with severe inflammation in the mu-
cosa and submucosa, while retaining the surface epi-
thelium; and grade 4, presence of mucosal ulcer with 
severe inflammation (infiltration of neutrophils, lym-
phocytes, and plasma cells) in the mucosa, submucosa, 
muscularis propria, and/ or submucosa. The scoring 
was performed on the entire colon and expressed as a 
mean average score/mouse.  
 
Measurement of plasma tumor necrosis 
factor  (TNF) concentrations 
After an overnight fast, blood was collected in 
EDTA-coated blood collection tubes, centrifuged at 
1,500 × g for 15 minutes at 4°C, and the supernatants 
collected. TNF levels were determined using com-
mercial assay kits, Mouse TNF Quantikaine ELISA 
kits (Cosmo Bio Co., ltd., Tokyo, Japan), according to 
the manufacturer's instructions. 
 
RNA extraction and quantification by re-
al-time PCR 
Total RNA was extracted from the colonic mucosa 
using the ISOGEN reagent (Nippon Gene Co., Ltd., 
Toyama, Japan) according to the manufacturer’s pro-
tocol. cDNA was then synthesized from total RNA 
using ReverTra Ace reverse transcriptase (TOYOBO Co., 
Osaka, Japan). Real-time PCR analysis of individual cDNA was 
performed using primers for mouse tumor necrosis factor 
TNFsense: TATGGCCCAGACCCTCACA, antisense: 
GGAGTAGACAAGGTACAACCCATC), cyclooxygenase2 
(COX2sense: CTGGAACATGGACTCACTCAGTTTG, 
antisense: AGGCCTTTGCCACTGCTTGTA), and interleukin 
1IL-1sense: TCCAGGATGAGGACATGAGCAC, anti-
sense: GAACGTCACACACCAGCAGGTTA), which were 
purchased from Takara Bio Inc. (Shiga, Japan). The 
18S-rRNA gene was used as an endogenous reference 
and it was amplified with a LightCycler (Light Cycler 
System ®1.5, Roche Diagnostics, Basel Schweiz) us-
ing SYBR® Premix DimerEraser™ (Takara Bio Inc.), 
THUNDERBIRD
®
 SYBR qPCR Mix (TOYOBO Co.), 
and specific primers (sense: GCAATTATTCCCCATGAACG, 
antisense: GGCCTCACTAAACCATCCAA). PCR cycling 
conditions were 95℃ for 30 sec, followed by 50 cycles 
of 95℃  for 5 sec, 55℃  for 10 sec (in case of 
THUNDERBIRD) or 30 sec (in case of DimerEraser) 
and 72℃ for 30 sec. The expression levels of the tar-
get gene were calculated by the relative standard curve 
method and were determined as ratios relative to 
18S-rRNA expression. Data are presented as 
fold-change values of treated samples relative to that 
of Group 1. 
 
Statistical analysis 
All of the data in this study were presented as mean ± 
SEM. The InStat Version 3.05 (Graph Pad Softwares, 
Inc., San Diego, USA) was used for statistical anal-
yses. Statistical significance was determined by 
one-way ANOVA, followed by a Tukey-Kramer Mul-
tiple Comparisons test or a two-tailed Student's t-test. 
Values of P < 0.05 were considered statistically sig-
nificant. 
 
Results 
General observation 
During the study, oral administration of DSS for five 
days induced acute colitis characterized by body 
weight loss in the TSNO (lean) mice, starting on day 6 
(Fig. 2a), and Group 2 (DSS alone) had a significant 
percent change in body weight compared with Group 1 
starting on day 7 (Fig. 2b). In TSNO mice, administra-
tion with ghrelin further reduced the body weight when 
compared to Group 2 (DSS alone), starting on day 5, 
when the difference in the reduction in body weight 
became statistically significant between the two groups 
and continued to be observed from day 5 to day 8 
(Group 2 vs. Group 4) and from day 7 to day 9 (Group 
2 vs. Group 3), respectively (P<0.05, Fig. 2b). At day 9, 
the changes in body weight of both Groups 3 and 4 
finally decreased, when compared to day 0, to 82% 
and 85%, respectively. On the other hand, body 
weights in the TSOD mice were comparable among 
the groups during the study, although Group 2 had a 
significantly reduction in body weight from day 7 (Fig. 
2). Liver weights on day 10 were comparable among 
the treatment groups of the TSNO and TSOD mice, 
although the values of TSOD mice were greater than 
those of the TSNO mice (Table 1). On day 10, treat-
ment of DSS, with or without ghrelin, increased the 
spleen weights in both genotypes (Table 1). Shortening 
of the colon length was observed in both TSNO and 
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TSOD mice treated with DSS (Group 2). In TSOD 
mice, DSS treatment significantly shortened the colon 
length (P < 0.05), while ghrelin treatment (Groups 3 
and 4) slightly elongated the colon length (Table 1). In 
both genotypes, simultaneous administration of DSS 
with ghrelin (Group 3) tended to reduce the shortening 
of colon length.  
 
Ghrelin did not affect colon damage and 
acute colitis induced by DSS 
The histopathological alterations in the colons were 
assessed on H&E-stained sections (Figure 3a), and the 
inflammation scores are shown in Figures 3b. In the 
control mice (Group 1), the colon presented normal 
morphology of crypts, abundant goblet cells, and a 
small number of lamina propria mononuclear cells. In 
both genotypes, there were no signs of mucosal thick-
ening and the complete absence of ulcerations was 
noted. However, in Group 2, DSS induced acute colitis 
with ulceration. Histological analysis revealed severe 
epithelial damage with extensive cellular infiltration 
into the submucosa, lamina propria, and colonic mu-
cosa; and depletion of goblet cells, mucosa thickening, 
and complete destruction of the architecture. These 
histological changes resulted in a high inflammation 
score were observed in both genotypes (Fig. 3b). The 
inflammation scores of Groups 3 and 4 in the TSOD 
mice were lower than the corresponding scores in the 
TSNO mice. In TSOD mice, treatment with ghrelin 
both reduced the infiltration of inflammatory cells into 
the submucosa and lamina propria and improved the 
loss of colonic crypts and epithelial cell necrosis. On 
the other hand, treatment with ghrelin did not improve 
these histological symptoms in TSNO mice. 
 
The timing of ghrelin administration resulted 
in different plasma TNF concentration 
Figure 4 shows the plasma TNF concentration in all 
groups of TSNO and TSOD mice. Administration of 
DSS alone (Group 2) increased serum TNF level 
when compared to that in the control (Group 1) in both 
genotypes. Administration of ghrelin combined with 
DSS (Group 3) tended to reduce serum TNF concen-
tration compared with that in the DSS alone group 
(Group 2) in both genotypes. On the other hand, treat-
ment with ghrelin after DSS exposure (Group 4) did 
not affect the level in TSNO mice, but increased TNF 
concentration in TSOD mice. In Group 4, the 
TNFlevel in TSOD mice was significantly higher 
than that in TSNO mice (P < 0.05).  
 
Ghrelin affected the mRNA levels of 
pro-inflammatory cytokines in the colonic mucosa 
Figure 5 presents the qRT-PCR-measured expression 
levels of pro-inflammatory cytokines that include 
TNFα (Figure 5a), COX-2 (Figure 5b), and IL-1 
(Figure 5c) in the colonic mucosa of the TSNO and 
TSOD mice. In the DSS alone group (Group 2), the 
expression of all three cytokines was higher than that 
in the control group (Group 1) in both genotypes. The 
expression of all of three cytokines in TSNO mice was 
higher than that in the TSOD mice in Group 2 (2.4-fold 
in TNF, 9.1-fold in COX-2, and 4.1-fold in IL-1b). 
Ghrelin treatment together with DSS (Group 3) tended 
to decrease the expression of TNF, COX-2and 
IL-1mRNAs in the TSNO mice. But, this treatment 
elevated the expression of both COX-2 and IL-1 in 
the TSOD mice. In contrast, ghrelin administration 
after DSS treatment (Group 4) elevated the expression 
of all three cytokines measured in both genotypes 
compared with that in Group 2.  
 
Discussion 
The involvement of obesity and the role of ghrelin 
in IBD have not been elucidated up to the present. In 
this study, we examined the differences of the an-
ti-inflammatory effects of ghrelin (simultaneous treat-
ment and post treatment) in both lean and obese mice. 
To accomplish the objectives, we used genetically pre-
disposed lean (TSNO) and obese (TSOD) mice to 
compare the effects of ghrelin on DSS-induced colitis. 
The results of this study showed that TSNO mice 
were induced colitis stronger than TSOD mice as evi-
dent from body weight change (Fig. 2) and expression 
of pro-inflammatory cytokines (Fig. 5). 
Pro-inflammatory cytokines are increased in colitis. 
Generally, these cytokines are increased in obesity [2, 
27]. Therefore, it is considered that obesity directly 
contributes to systemic inflammation. Several studies 
have reported a relationship between obesity and the 
levels of inflammatory proteins such as TNF, IL-1, 
IL-6, and others [2, 27]. Furthermore, other studies 
have suggested that adipokines, secreted by adipose 
tissue, are closely associated with UC [10, 14, 18, 23, 
29]. Therefore, it was hypothesized that TSOD mice 
would have more serious DSS-induced colitis com-
pared with TSNO mice, but unexpected results were 
obtained in this study (i.e., TSNO mice had more seri-
ous DSS-induced colitis). The causal relationship be-
tween obesity and colitis remains unclear till now. 
Teixeira et al. [26] reported that obese mice had both 
prolonged and aggravated DSS-induced inflammatory 
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manifestations of UC rather than lean mice, whereas 
Hyland et al. [8] reported that trinitrobenzene sulfonic 
acid (TNBS)-induced colitis was significantly reduced 
in diet-induced obese rats compared with diet-resistant 
rats. Further research will be therefore required to gain 
a better understanding about the complex relationship 
between obesity and colitis.  
There are some reports supporting the an-
ti-inflammatory effects of exogenous ghrelin on colitis 
in lean animals [6, 15, 16]. Although many researchers 
reported that ghrelin has an anti-inflammatory effect in 
colitis, in this study, a clear anti-inflammatory effect of 
exogenous ghrelin (70 nmol/kg, bw) was not observed 
in the TSNO mice. De Smet et al. [5] reported that 
post-treatment with ghrelin (100 nmol/kg, twice daily) 
for 5 or 10 days enhanced the clinical disease activity 
and promoted infiltration of neutrophils and colonic 
IL-1 levels in DSS-induced colitis. Siegl et al. [22] 
reported that ghrelin (0.5 μg/g: 148.4 nmol/kg, bw, 
twice a day, i.p.) conferred protective effects during the 
early phase of sepsis, but during the later phase, 
ghrelin administration deteriorated both immune re-
sponse and outcome in a mouse peritonitis model. 
Although many differences exist among previous 
ghrelin studies regarding its dose and treatment sched-
ule, it was thought that post-treatment with high-dose 
ghrelin (more than 100 nmol/kg, bw) for long periods, 
might aggravate colitis. Therefore, our results might 
have been different if we tried to decrease both the 
dose of ghrelin and the duration of administration. 
These modifications might have enabled ghrelin to 
ameliorate the colitis more clearly in the lean TSNO 
mice.  
Some of the differences were observed in the results 
from TNSO (lean) and TSOD (obese) mice. Ghrelin 
administration did not affect body weight change and 
ameliorated the inflammation score in TNOD mice but 
not in TNSO mice. In addition, in this study, the result 
of plasma TNF concentration did not correlate with 
that of TNF mRNA expression in the colonic mucosa. 
In fact, TSOD mice that were treated with exogenous 
ghrelin after DSS administration (Group 4) had in-
creased plasma TNF concentrations, whereas similar 
effect was not observed in TSNO mice. On the other 
hand, the same treatment increased the expression of 
TNF mRNA in the colonic mucosa of TSNO mice, 
but did not affect that of TSOD mice. Although it re-
mains a matter of speculation, it was thought that ex-
ogenous ghrelin treatment after DSS administration 
exacerbated the pre-existing colitis in TSNO mice, but 
did not affect plasma TNF concentration. In contrast, 
the increase in plasma TNF concentration of Group 4 
in TSOD mice could be due to the secretion of adi-
pokines and TNF from adipocytes following admin-
istration of ghrelin immediately before sampling, but 
was not colitis related. There are relatively few reports 
investigating the effects of exogenous ghrelin on obe-
sity in animals. Using a peritonitis mouse model, Siegl 
et al. [22] demonstrated that ghrelin treatment im-
proved survival, ameliorated hypothermia and in-
creased hyperleptinemia in obese mice compared to 
that in lean controls. This is partially in accordance 
with our results. Because it has been unclear whether 
ghrelin exerts some beneficial effects in obese animals, 
the modifying effects of ghrelin on some pathological 
condition, such as colitis in obese animals, warrant 
further study.  
Although the present study could not elucidate the 
differences in the anti-inflammatory effects of exoge-
nous ghrelin between lean and obese mice, at least it is 
clarified that ghrelin-induced effects are different in 
the administration timing of ghrelin or genotypes. In-
terestingly, it has been reported that exogenous ghrelin 
(3 nmol/day, i.p.), which was administered during the 
DSS-treatment periods, significantly suppressed tumor 
incidence in the inflammation-associated colon car-
cinogenesis model [11]. Additionally, ghrelin has been 
expected to be a target for treating cachexia because of 
its multiple actions, including increasing food intake, 
decreasing energy expenditure and inflammation, in-
creasing growth hormone, and direct anabolic effect on 
the skeletal muscles and adipose tissue [17]. However, 
in the present study, some of the data showed that 
ghrelin administration tended to aggravate 
DSS-induced colitis in both lean and obese mice. 
Therefore, it is necessary to consider carefully the po-
tentially high risk of aggravating the pathological con-
dition depending on the administration timing or dos-
age of ghrelin and the genotype.  
The current study is the first to compare and inves-
tigate the chemopreventive effect of ghrelin on colitis 
using both lean and obese mouse models and at differ-
ent administration schedule. The findings in the pre-
sent study suggests that it is necessary to consider both 
individual’s body mass and administration timing 
when ghrelin-induced anti-inflammatory effects are 
assessed in colitis.  
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和文摘要 
肥満と非肥満状態のマウスに誘起した大腸炎に対す
るグレリンの抗炎症効果に差があるか否か明らかにす
ることを目的として、肥満モデルマウス及びその野生型
マウスを用いて dextran sodium sulfate （DSS）誘発大腸
炎に対するグレリン投与（同時処置と後処置）の影響を
検討した。野生型(TSNO)及び肥満型(TSOD)マウス各 24
匹を 1 群 6 匹とし、無処置群（1 群）、DSS 単独投与群
（2群）、DSS 及びグレリン同時投与群（3群）、DSS 投
与後グレリン処置群（4群）を設定した。炎症の指標と
して、体重、大腸長、ELISA による血中 TNF濃度解析、
大腸のHE染色による炎症スコア解析及び摘出した大腸
の炎症性サイトカイン mRNA 発現の解析を行なった。
HE染色による炎症像及び炎症性サイトカインmRNAの
発現の結果から TSOD マウスと比べ TSNO マウスの方
で炎症が顕著だった。グレリン投与（70 nmol/kg BW）
に対しては、TSNO マウスでは、いずれの処置でも体重
減少が見られたが、炎症スコア、血中 TNF濃度には変
化が見られなかった。また、炎症性サイトカインの発現
は、同時処置で若干改善傾向が見られたが、後処置によ
り悪化する傾向が観察された。TSOD マウスでは、体重
に変化は見られなかったが、炎症スコアの若干の改善が
見られた。しかし、血中 TNFおよび炎症性サイトカイ
ンの発現に関して、改善傾向は見られなかった。以上、
グレリン 70 nmol/kg の腹腔内投与では明確な抗炎症効
果が得られないこと、グレリンの大腸炎に対する抗炎症
効果は、適用スケジュールと肥満の程度で差が出る可能
性が本実験により示された。すなわち、グレリンの抗炎
症効果を観察する際には、投与量や投与スケジュール、
動物の状態を慎重に考慮する必要性があることが示唆
された。 
 
キーワード：潰瘍性大腸炎、肥満、グレリン、マウス 
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Fig. 1 The treatment protocol for the experiment (see Materials and Methods) 
Fig. 2 Effect of ghrelin administration on body weight in TSNO (lean) and TSOD (obese) mice with DSS-induced 
colitis. Data from 6 mice are indicated for each group. (a) Upper 4 data indicate for TSOD mice of body weight. 
Lower 4 data indicate for TSNO mice of body weight. (b) Percent change in body weight. aP< 0.05 between G1 and 
G2. bP< 0.05 between G2 and G3. cP< 0.05 between G2 and G4. 
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Fig. 3 Histological analysis of distal colon in day 10 (a) Histology of the distal colon (H&E stain). Bar, 0.1 mm. (b) 
Inflammation score. Data from 3 mice are indicated for each group. 
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Fig. 4 Plasma TNF concentration (mean±SEM) of each group in TSNO and TSOD mice. Data from 4 to 6 mice 
are indicated for each group. *P< 0.05. Significant difference between TNSO and TSOD mice. 
Fig. 5 Quantification of proinflammatory cytokine mRNA levels by real-time RT-PCR in colon tissue (mean±SEM, 
n=3 to 6 for each group). Whole mRNA levels are indicated for that of G1 converted in to one. (a): TNF, (b): 
COX-2, (c): IL-1. **P< 0.01. Significant difference between TNSO and TSOD mice. 
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